MSLN and ovarian carcinoma: Targeting MSLN for immunotherapy is based on observations of increased MSLN-specific antibodies detected in sera of about 40% of patients with mesothelioma and 42% of patients with ovarian cancer, indicating that antibody responses to MSLN was correlated with higher expression levels of MSLN on the surface of cancer cells (12).